
Feature|Videos|January 2, 2025
Patient Selection and Recruitment for Clinical Trials
Obtaining the right patient population for a CAR T-cell clinical trial is based off several factors from both the patient and the site.
Advertisement
Episodes in this series

Patient selection is a key component to the success of a clinical trial. A CAR T-cell study protocol is critical in outlining the site, the desired patient diagnosis, biomarkers of the tumor, and prior treatments. Building on key components from episode seven of collaboration, the panelists outline how working close with sites allow for stronger patient selection.
Advertisement
Related to this article

Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.

Innogen grants Arcera exclusive rights to its long-acting GLP-1 receptor agonist across Africa, Eastern Europe, Latin America and the Middle East.

With rising healthcare costs, practices are embracing flexible payment models and upfront pricing transparency to keep care accessible.

Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.

Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.

DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
Advertisement
Advertisement
Trending on PharmExec
1
Sanofi Eyes Insmed in Potential $43B Deal as Dupixent Patent Clock Ticks
2
Pfizer, Verismo Strike Licensing Deals to Push CAR T Manufacturing In Vivo
3
FDA Approves Livsayis, Regeneron's First siRNA Therapy for Myasthenia Gravis
4
How Pharma Organizations Can Scale AI Agents and Stay Audit-Ready
5










